Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-945-7361
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees61
Next Earnings Date2/28/2019 (Estimated)
OptionableNot Optionable
Translate Bio (NASDAQ:TBIO) Frequently Asked Questions
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
How were Translate Bio's earnings last quarter?
Translate Bio Inc (NASDAQ:TBIO) posted its earnings results on Thursday, August, 9th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $3.64. View Translate Bio's Earnings History.
When is Translate Bio's next earnings date?
What price target have analysts set for TBIO?
4 Wall Street analysts have issued 12 month price objectives for Translate Bio's shares. Their forecasts range from $20.00 to $25.00. On average, they anticipate Translate Bio's stock price to reach $22.75 in the next twelve months. This suggests a possible upside of 161.5% from the stock's current price. View Analyst Price Targets for Translate Bio.
What is the consensus analysts' recommendation for Translate Bio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Translate Bio.
Has Translate Bio been receiving favorable news coverage?
Media stories about TBIO stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Translate Bio earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the next few days.
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Audentes Therapeutics (BOLD), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Coherus Biosciences (CHRS), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL), BAVARIAN NORDIC/S (BVNRY) and Heska (HSKA).
What other stocks do shareholders of Translate Bio own?
Who are Translate Bio's key executives?
Translate Bio's management team includes the folowing people:
- Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)
- Dr. Michael W. Heartlein, Chief Scientific Officer & CTO (Age 60)
- Mr. John R. Schroer CFA, CFO & Treasurer (Age 54)
- Mr. Paul D. Burgess J.D., Gen. Counsel (Age 46)
- Ms. Paula A. Cloghessy, Sr. VP of Human Resource (Age 48)
When did Translate Bio IPO?
(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.
When did the company's lock-up period expire?
Translate Bio's lock-up period expired on Tuesday, December 25th. Translate Bio had issued 9,350,000 shares in its public offering on June 28th. The total size of the offering was $121,550,000 based on an initial share price of $13.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who are Translate Bio's major shareholders?
Translate Bio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Atlas Venture Advisors Inc. (8.69%), BlackRock Inc. (2.18%), Perceptive Advisors LLC (0.96%), Sphera Funds Management LTD. (0.69%), Geode Capital Management LLC (0.26%) and Northern Trust Corp (0.25%). Company insiders that own Translate Bio stock include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Institutional Ownership Trends for Translate Bio.
Which major investors are selling Translate Bio stock?
Which major investors are buying Translate Bio stock?
TBIO stock was acquired by a variety of institutional investors in the last quarter, including Atlas Venture Advisors Inc., BlackRock Inc., Fosun International Ltd, Geode Capital Management LLC, Sphera Funds Management LTD., Two Sigma Investments LP, Bank of New York Mellon Corp and Northern Trust Corp. Company insiders that have bought Translate Bio stock in the last two years include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Insider Buying and Selling for Translate Bio.
How do I buy shares of Translate Bio?
Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Translate Bio's stock price today?
One share of TBIO stock can currently be purchased for approximately $8.70.
How big of a company is Translate Bio?
Translate Bio has a market capitalization of $392.72 million. Translate Bio employs 61 workers across the globe.
What is Translate Bio's official website?
How can I contact Translate Bio?
Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.
MarketBeat Community Rating for Translate Bio (NASDAQ TBIO)
MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote "Outperform" if you believe TBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
